Kyle joined Pappas Capital in 2018, bringing with him extensive experience in clinical pharmacology, basic science and healthcare equity research. Prior to joining Pappas, he was an equity research analyst and Vice President at T. Rowe Price in Baltimore, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments for all T. Rowe Price funds. During his time at T. Rowe, Kyle led the firm's IPO investment in Pappas portfolio company CoLucid Pharmaceuticals (NASDAQ: CLCD), which was eventually sold to Eli Lilly for just under $1 billion. Prior to joining T. Rowe, Kyle was an equity research associate and Vice President at Cowen and Company in Boston, where he covered global pharmaceutical equities. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to several high-profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS.
Kyle currently serves as a director for Allievex, and as a board observer for CuraSen Therapeutics and Ribometrix. He previously served as a director for Balance Therapeutics, and as an observer for Mirum Pharmaceuticals and VelosBio. Kyle also serves on the boards of the Council for Entrepreneurial Development (CED) and the NC Biosciences Organization (NCBIO).
Medical University of South Carolina (PhD in Pharmaceutical and Biomedical Sciences)
Medical University of South Carolina (Doctor of Pharmacy/PharmD)
The Citadel (MBA)